LLS News Network

News and Information from The Leukemia & Lymphoma Society

LLS Statement on Inauguration Day 2021

Our right to vote is the heart of our democracy, as is a free and fair election. The democratic process is critical to our work at The Leukemia & Lymphoma Society where civic engagement is a cornerstone of our values. Every day, LLS works directly with lawmakers at the state and federal levels to advance policies that serve the best interests of blood cancer patients. Every member of the LLS community – staff, ...

FDA Approval: Treatment Advance for Patients with Rare Blood Cell...

Rye Brook, N.Y. (January 19, 2021) – On January 15, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with newly diagnosed light chain (AL) amyloidosis, a rare and serious blood cell disorder that may occur by itself or with myeloma. Daratumumab is used in combination with chemotherapy agents bortezomib (Velcade®) and cyclophosphamide (C...

The Leukemia & Lymphoma Society Applauds Bipartisan Agreement to ...

Rye Brook, NY (December 21, 2020) - The Leukemia & Lymphoma Society issues the following statement in response to Congress including policies designed to protect patients from surprise medical bills in the stimulus bill scheduled for a vote Monday, Dec. 21, 2020: LLS applauds Congress for reaching a bipartisan agreement that will, after years of work, hold patients harmless from surprise medical bills.  ...

FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOM...

Rye Brook, N.Y. (December 18, 2020) – The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one prior type of treatment. Selinexor is used in combination with the chemotherapy drug bortezomib (Velcade®) and the corticosteroid dexamethasone in these patients. LLS supported development of selinexor with over $4 million i...

The Leukemia & Lymphoma Society Statement on COVID-19 Vaccine Dis...

At The Leukemia & Lymphoma Society (LLS), we hear from blood cancer patients and caregivers each day about the profound effects of the COVID-19 pandemic on their cancer care, treatment, and daily lives. As a patient-focused leader in the scientific and medical community, we are encouraged by the U.S. Food & Drug Administration (FDA) decision to grant emergency use authorization (EUA) to the first COVID-19 vac...

Collaboration Driving Progress: LLS Forms Alliances with Leading ...

Rye Brook, NY (December 14, 2020) – As the world confronts a viral pandemic not seen in the past 100 years, the reverberations are being felt across every sector, from healthcare to the economy, education, business and science, including the blood cancer community. Blood cancers don’t stop for the Covid-19 virus and the urgent need for collaboration to address these challenges has never been starker. In respon...

Media Requests

Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.